The Association of Public Health Laboratories (APHL) held its annual Newborn Screening Symposium from October 5–9 in Providence, Rhode Island, bringing together approximately 570 scientists and healthcare professionals from across the United States and around the world. The symposium addressed a broad range of topics critical to public health newborn screening systems, including enhanced biochemical and molecular screening technologies; methods for detecting new conditions; quality improvement initiatives; strateg

Dr. Joseph Orsini, Deputy Director of the Newborn Screening Program at the Wadsworth Center, has been honored with the 2025 George Cunningham Visionary Award in Newborn Screening. This prestigious lifetime achievement award recognizes individuals working in U.S.

The Wadsworth Center’s Mycology Laboratory has developed an in-house MALDI-TOF MS (matrix-assisted laser desorption ionization - time of flight mass spectrometry) library comprising rare yeast species, which is now one of the contributed databases available through the CDC’s MicrobeNet platform.

Approximately half of all cases of reported infertility in the United States involve malefactor, which is commonly diagnosed via standardized analysis of semen quality parameters that include sperm concentration, motility, and morphology.  

The New York State Newborn Screening Program housed at the Wadsworth Center was the first program in the U.S. to implement screening for sickle cell disease in 1975. Sickle cell disease is an inherited blood disorder affecting hemoglobin, the major protein that carries oxygen in red blood cells. The abnormal hemoglobin causes sickle-shaped red blood cells that can break down prematurely and/or block blood flow, leading to anemia, pain, infections, and other severe complications. Sickle cell disease affects more than 100,000 people in the U.S.

September is designated as Public Health Laboratory Appreciation Month. Wadsworth Center proudly joined the Association of Public Health Laboratories and colleagues nationwide in honoring the vital role these laboratories—and every individual within them—play in protecting public health. 

Read the New York State Department of Health Press Release.

Read the Association of Public Health Laboratories' Blog post spotlighting Wadsworth Center scientist Jean Rock.

In August, Brooke Clemons of the Parasitology Laboratory and Kiran Mall of the Protein Expression and Biochemistry Core Laboratories graduated from the Association of Public Health Laboratories (APHL) Emerging Leader Program (ELP), Cohort 18.  They were selected as two of 25 participants nationwide for this yearlong program designed to cultivate leadership skills among laboratory professionals from state and local public health laboratories.  

The Wadsworth Center Biodefense Laboratory has been awarded $125,000 to develop, optimize, and validate threat-agnostic sequencing workflows for the rapid detection of pathogens in respiratory and other specimens. This project represents a critical step in strengthening New York State’s laboratory readiness and capacity to respond to infectious disease threats.  The initiative will integrate metagenomic and targeted sequencing methods with the Johns Hopkins University Applied Physics Laboratory Basestack software, including its TaxTriage module. 

Minneapolis, MN | September 7-9, 2025 – Dr. Norma Tavakoli, PhD, of the Wadsworth Center was a featured speaker at the Congenital Cytomegalovirus (cCMV) Public Health and Policy Conference, hosted by the University of Minnesota.  Her presentation, “A Pilot Study in New York State to Screen Newborns for Congenital Cytomegalovirus,” highlighted groundbreaking work conducted by the New York State Newborn Screening Program.  

The New York State Newborn Screening Program at the Wadsworth Center has become the first program in the United States to implement universal newborn screening for Metachromatic Leukodystrophy (MLD), a devastating but now treatable lysosomal storage disorder.  MLD is caused by low or absent activity of the arylsulfatase A (ARSA) enzyme, leading to toxic accumulation of sulfatides and progressive damage to the nervous system.

Wadsworth Center senior scientists Drs. Janice D. Pata, Lili Kuo, and Paul S.

The Wadsworth Center was prominently represented at the annual Molecular Genetics of Bacteria and Phages meeting (“Phages”) in Madison, Wisconsin – one of the premier international conferences in microbial genetics.  The meeting drew more than 350 researchers from around the world, spanning senior investigators to first-year trainees.  

The New York State (NYS) Newborn Screening Program (NBSP) became the first state in the nation to screen for sickle cell disease in 1975. Sickle cell disease is an inherited blood disorder, known also as hemoglobinopathy, that affects the shape and function of red blood cells in the body. It can cause anemia, painful episodes, infections, stroke/blood clots, and organ damage. If left untreated, this condition can cause significant illness and early death. Fortunately, with early diagnosis and treatment, health outcomes can be significantly improved.

A National Institutes of Health (NIH) Training Grant (T32) titled “RNA Science and Technology in Health and Disease” was awarded to the University at Albany, State University of New York, for $1.8 million over the next five years to support seven RNA Fellows each year from the graduate education programs that comprise the RNA Institute.  

Drs. Pallavi Ghosh and

Read the Association of Public Health Laboratories' blog and interview with Wadsworth Center's own Rabies Laboratory Director, Dr. April Davis.

Dr. Joseph Orsini, Director of the Newborn Screening Program’s Biochemical Genetics Laboratory, represented the Wadsworth Center at the Hunter’s Hope Medical Symposium, held July 15-16, 2025, in Ellicottville, NY. He has attended this annual symposium since 2008, which brings together scientists, clinicians, newborn screening professionals, and families to advance understanding of Krabbe Disease and other leukodystrophies. 

The Wadsworth Center, the public health laboratory of the New York State Department of Health, has been selected to serve as the central reference testing laboratory for a major international clinical trial aimed at preventing multidrug-resistant tuberculosis (MDR-TB) in vulnerable populations.